Registration of a U. S. Patent for Treatment of Influenza Virus Infection through Joint Application with Tokushima University

SBI Pharmaceuticals Co., Ltd.

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in the United States of America for the treatment of influenza virus infection.

This patent was filed jointly with Tokushima University (Main campus: Tokushima-city; President: Sumihare Noji).

U. S. Patent number: US 9,351,949 B2
Title of invention : Prophylactic/ Therapeutic Agent for Influenza Virus Infection
Assignee s : SBI Pharmaceuticals Co., Ltd. Tokushima University
Filing date: June 3 , 201 3

The corresponding patent was registered in Japan as of April 22, 2016. (Please refer to our news release dated May 18, 2016.)

SBI Pharmaceuticals will continue to pursue various potential applications of 5-ALA, and focus on research and development to provide pharmaceuticals that satisfy the unmet medical needs of as many people as possible around the world.

*: 5-aminolevulinic acid (5-ALA)

An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

For further information, please contact:
SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81-3-6229-0095

Please download PDF File

Mechanical Translations by Google »